心先安与洋地黄治疗顽固性心力衰竭的对比研究  

作　　者：李蕾[1] 周勇[1] 任骋[1] 姚云婕[1] 

机构地区：[1]江苏苏州大学附属张家港医院心内科,215600

出　　处：《当代医学》2009年第27期92-93,共2页Contemporary Medicine

摘　　要：目的比较心先安与洋地黄两种药物治疗顽固性心力衰竭的临床疗效,探讨心先安的疗效及安全性。方法回顾性分析2000年1月～2008年1月顽固性心力衰竭患者136例,心先安组与洋地黄组各68例;通过比较两组治疗后的临床症状与体征的改善率及超声心动图心功能指标的改善率来评估两种药物的疗效。结果心先安组临床表现改善率优于洋地黄组,差异有统计学意义(P<0.05);心先安组的心功能各项指标优于洋地黄组,差异有统计学意义(P<0.05)。结论心先安治疗顽固性心力衰竭疗效优于洋地黄,是一种安全可靠的有效药物。Objective To compare the clinic efficacy of meglumine cyclic adenylate （MCA） and digitalis （DIG） in the treatment of intractable heart failure （IHF）, and to explore the clinical efficacy and safety of MCA in patients with IHF. Methods The clinical data of patients with IHF from January 2000 to January 2008 were retrospectively analyzed. 136 patients were selected and divided into Group MCA and Group DIG. Each group had 68 patients and the clinical data had comparability between two groups. The effective rates of clinical situation （symptoms and signs） and functional parameters of ultrasonic cardiogram （UCG） were used to evaluate the efficacy of MCA and DIG. Results There were different statistical significance in the effective rates of clinical situation （symptoms and signs） between Group MCA and Group DIG （P〈0.05）. There were different statistical significance in the effective rates of functional parameters of UCG between the two groups （P〈0.05）, and the rates in Group MCA were better than ones in Group DIG. Conclusions The clinic efficacy of MCA is better than one of DIG in the treatment of IHF. MCA is a safe and effective medicine for patients with IHF.

关 键 词：顽固性心力衰竭 心先安 洋地黄 药物治疗 

分 类 号：R541.6[医药卫生—心血管疾病] R972.1[医药卫生—内科学]